MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“MediPharm”, the “Company”, or “we”), a pharmaceutical company specialized in precision-based cannabinoids, today provided its shareholders with information related to three of the six directors (the “Dissident Nominees”) nominated by Apollo Technology Capital Corporation (“Apollo”) to stand for election at MediPharm’s Annual and Special Meeting of Shareholders on June 16, 2025. All dollar figures in this news release are in U.S. dollars.
MediPharm Achieves Key Milestone Toward $4.5 Million Cash Sale of Hope Facility, On Track to Close in JuneTORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the removal of all conditions precedent, related to its previously-announced agreement (the “Purchase Agreement”) for the sale of MediPharm’s facility in Hope, BC, (“Hope Facility”) to Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) for $4.5 million in cash (the “Transaction”).
MediPharm Labs Alerts Shareholders to Allegations Made Against Regan McGee in Multiple Litigation FilingsTORONTO, May 21, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today alerted its shareholders to publicly available information about Regan McGee, the controlling shareholder, director, Chairman and CEO of Apollo Technology Capital Corporation (“Apollo”), a dissident MediPharm shareholder. Apollo filed an amended and restated dissident proxy circular on May 20, 2025 (the “Dissident Circular”) seeking to elect Mr. McGee and five other directors to the MediPharm board of directors at the Company’s Annual and Special Meeting of Shareholders scheduled for June 16, 2025 (the “Meeting”).
